Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073159 | 0.80 | ALDH1A1 (0.35) | MAPTKDM4E | |
| SCHEMBL10073652 | 0.78 | ALDH1A1 (0.33) | MAPT | |
| SCHEMBL10072917 | 0.77 | GCK (0.36) | NEK1LMNA | |
| SCHEMBL10072923 | 0.75 | NEK1 (0.59) | NEK1 | |
| SCHEMBL10073459 | 0.75 | SMN1; SMN2 (0.36) | KMT2AGAA | |
| SCHEMBL10073639 | 0.74 | MET (0.33) | KMT2ALMNAPKMSLC40A1 | |
| SCHEMBL10072941 | 0.72 | MAPK1 (0.39) | — | |
| SCHEMBL10073849 | 0.71 | NR3C1 (0.36) | MAPTSLC40A1KDM4E | |
| SCHEMBL10073162 | 0.71 | NR3C1 (0.42) | PKMKDM4E | |
| SCHEMBL10072910 | 0.71 | ALOX5AP (0.36) | KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445681-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017781-B2 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007059219-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | PRKDC, MAP3K20, PRKACA | KMT2A 649/4885NEK1 243/4885LMNA 3403/4885 |
| US-20120165367-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | PRKDC, MAP3K20, PRKACA | KMT2A 649/4885NEK1 243/4885LMNA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.